Immunovant, Inc. (IMVT) Research

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Market snapshot

Symbol
IMVT
Price
$35.34
Day change
+1.82%
Market cap
$7.3B
P/E ratio
-14.24x
52-week range
14.32-36.285
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$45.00

Recent news

  • These Analysts Increase Their Forecasts On Immunovant After Q4 Results

    Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.

  • Immunovant Stock Surges Despite Disappointing Earnings Miss

    Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a wider fourth‑quarter loss than analysts expected.

  • Immunovant's treatment for eye disease fails late-stage trial

    Immunovant ​said on ‌Thursday ​that ​its therapy ⁠to ​treat a ​type of ​eye ​disease failed to ‌meet ⁠the main ​goals ​in ⁠a ​late-stage ​study.

Peer companies

  • ACADIA Pharmaceuticals Inc. (ACAD)
  • Akero Therapeutics, Inc. (AKRO)
  • Crinetics Pharmaceuticals, Inc. (CRNX)
  • Dyne Therapeutics, Inc. (DYN)
  • Kymera Therapeutics, Inc. (KYMR)
  • NewAmsterdam Pharma Company N.V. (NAMS)
  • Praxis Precision Medicines, Inc. (PRAX)
  • Ultragenyx Pharmaceutical Inc. (RARE)

Recent insider activity

  • Pande Atul — M-Exempt (1500 shares) on 2026-06-15
  • Pande Atul — S-Sale (1500 shares) on 2026-06-15
  • Pande Atul — M-Exempt (1500 shares) on 2026-06-15
  • Fromkin Andrew J. — M-Exempt (16260 shares) on 2026-05-28
  • Fromkin Andrew J. — S-Sale (11483 shares) on 2026-05-28

Open Immunovant, Inc. (IMVT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.